Revenue Breakdown
Composition ()
No data
Revenue Streams
Dr Reddy's Laboratories Ltd (RDY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Global Generics, accounting for 89.2% of total sales, equivalent to $899.51M. Other significant revenue streams include Pharmaceutical Services and Active Ingredients and Other. Understanding this composition is critical for investors evaluating how RDY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Dr Reddy's Laboratories Ltd maintains a gross margin of 53.63%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.30%, while the net margin is 13.63%. These profitability ratios, combined with a Return on Equity (ROE) of 16.55%, provide a clear picture of how effectively RDY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, RDY competes directly with industry leaders such as NVO and LLY. With a market capitalization of $11.97B, it holds a significant position in the sector. When comparing efficiency, RDY's gross margin of 53.63% stands against NVO's 80.86% and LLY's 82.52%. Such benchmarking helps identify whether Dr Reddy's Laboratories Ltd is trading at a premium or discount relative to its financial performance.
